Skip to content

Effect of genetics on response to vitamin D supplementation in adults with asthma: a randomised controlled trial

Vitamin D receptor gene variations and influence on asthma control with Vitamin D3 supplementation in adults with asthma: a pilot randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/02/049590
Enrollment
40
Registered
2023-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J45- Asthma

Interventions

Intervention1: Vitamin D3 supplementation as add on to standard therapy: Vitamin D3: Oral powder 60,000 IU/week for 2 months Standard therapy: Inhaled corticosteroids and beta 2 agonists Control Inter

Sponsors

University of Health Sciences Rohtak
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinician diagnosed asthma 2. Baseline serum vitamin D levels 3. History of = 1 exacerbation in the last 12 months

Exclusion criteria

Exclusion criteria: 1. Chronic respiratory disorders other than asthma 2. Chronic oral corticosteroid therapy 3. Already on vitamin D supplementation 4. Unwillingness to participate in study

Design outcomes

Secondary

MeasureTime frame
? Change in pulmonary function test using spirometry.Timepoint: 0, 1, 2, 3, 4, 5 and 6 months;? Change in asthma control levels using GINA asthma control questionnaire (ACQ).Timepoint: 0,1,2,3,4,5,6 months;? Ability to achieve 50% reduction in inhaled corticosteroids (ICS) doseTimepoint: 0,1,2,3,4,5,6 months;? Average cumulative dose of ICSTimepoint: 6 months;? Change in quality of life using Asthma Quality of Life Questionnaire (AQLQ).Timepoint: 0 and 6 months;? Incidence of study withdrawals due to worsening asthma or treatment related adverse events.Timepoint: 6 months

Primary

MeasureTime frame
?Association of different vitamin D receptor (VDR) SNPs with incidence and time to severe asthma exacerbations in two treatment arms.Timepoint: Baseline and 6 months

Countries

India

Contacts

Public ContactDr Niti Mittal

PGIMS, Rohtak

drniti.mittal@gmail.com8059840290

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026